Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Injection crawled time : 12:07 save search
Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis
Published: 2020-09-08 (Crawled : 12:07) - globenewswire.com
SPRO | $1.5 2.04% 2.0% 210K
|
Health Technology
|
| O: 3.35%
H: 54.43%
C: 41.14%
positive results phase 3 trial topline injection infections
Spero Therapeutics Hosting Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections
Published: 2020-09-24 (Crawled : 12:07) - globenewswire.com
SPRO | $1.5 2.04% 2.0% 210K
|
Health Technology
|
| O: -0.64%
H: 4.16%
C: 0.21%
treatment injection infections
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 49.67% 1.4M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
HOLO | $2.24 -5.49% 27.74% 7.7M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
VIAO | $0.262 0.77% 16.03% 14M
|
Electronic Technology
DXF | $0.2708 -5.71% 14.48% 190K
|
Finance
GRFX | $0.2159 -10.04% 12.55% 5.9K
|
n/a
BHIL | $0.1722 -3.8% 12.08% 290K
|
Agriculture, Forestry, Fishing ...
MCW 4 | $6.49 -1.22% 10.94% 6
|
Professional, Scientific, and T...
Your saved searches
Save your searches and get alerts when important news are released.